EUVIMEDEUVIMED entdecken
Klinische Studie

First-in-human experience and one-year outcomes using a novel conformal pulsed-field ablation balloon catheter for pulmonary vein isolation in paroxysmal atrial fibrillation

Shiqiang Xiong, Duan Luo, Yan Luo, Guoshu Yang, Guijun He, Yongxin Yang, Jialing He, Bao Xu, Lin Cai, Long Huang, Hao Chen, George Thomas und 3 weitere

Journal of Interventional Cardiac Electrophysiology · 10.10.2026 · 69 (9) · 3157-3167

DOI: 10.1007/s10840-026-02447-y ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Journal of Interventional Cardiac Electrophysiology, online erschienen am 10.10.2026. Verfasst von Shiqiang Xiong und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Affiliated Hospital of Southwest Jiaotong University, The Third People's Hospital of Chengdu, Chengdu, Sichuan, China. Hauptthemen laut MEDLINE: Atrial Fibrillation, Catheter Ablation, Pulmonary Veins. Die Arbeit nennt 46 Literaturangaben. Gefördert von: Liu Hanxiong Famous Doctor Studio of Chengdu.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Thermal balloon catheters have improved the efficiency of pulmonary vein isolation (PVI) in atrial fibrillation (AF). Reports assessing additional safety and effectiveness of pulsed field ablation (PFA) balloon catheters for PVI are limited. This study aims to assess the safety and effectiveness of a conformal PFA balloon catheter for PVI in paroxysmal AF.

Methods

35 patients with paroxysmal AF (PAF) were treated with a PFBalloon catheter (Biphasic, Bipolar, 750 V). The balloon was inflated with 10:1 saline/contrast, with volume adjusted for spherical wide-antral or pear-shaped ostial-junction PV ablation to ensure optimal tissue contact. The primary safety endpoint was absence of periprocedural primary adverse events. The primary effectiveness endpoint was acute PVI. The secondary effectiveness endpoint included durable PVI assessed by remapping at three months post-ablation and 1-year clinical outcomes.

Results

All targeted PVs (142/142) in 35 patients were acutely isolated, with 32.3 ± 4.5 applications per patient and 7.9 ± 1.0 per vein. Procedure and left atrial dwell times were 133 ± 46 and 56 ± 25 min, respectively. No hemolysis-related acute kidney injury or severe device-related complications occurred. PVI durability was 76.0% (19/25) per patient and 93.1% (95/102) per vein. After a median follow-up of 367 (interquartile range 357–380) days, 1-year Kaplan-Meier estimate for freedom from atrial arrhythmia (AF/atrial flutter/atrial tachycardia) ≥30 s was 90.7% (95% CI, 81.2%–100%).

Conclusions

The conformal PFBalloon catheter demonstrated favorable safety, efficiency, and effectiveness for PVI in PAF patients, achieving durable lesions and a high rate of freedom from atrial arrhythmias recurrence. Trial registration clinicaltrials.gov NCT07320976.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationCatheter AblationPulmonary VeinsFemaleHumansMaleMiddle AgedEquipment DesignIrreversible Electroporation TherapyTreatment Outcome

Stichwörter der Autor:innen

Balloon catheterInvasive remappingParoxysmal atrial fibrillationPulmonary vein isolationPulsed-field AblationRecurrence

Autor:innen und Institutionen

  • Department of Cardiology, Affiliated Hospital of Southwest Jiaotong University, The Third People's Hospital of Chengdu, Chengdu, Sichuan, China.
  • EnChannel Medical Inc, Guangzhou, China.
  • Department of Medicine, Division of Cardiology, Cornell University Medical Center, New York, US.
  • Department of Cardiology, John Radcliffe Hospital, Oxford, UK.
  • Department of Cardiology, Affiliated Hospital of Southwest Jiaotong University, The Third People's Hospital of Chengdu, Chengdu, Sichuan, China. zhangzhen@swjtu.edu.cn.
  • Department of Cardiology, Affiliated Hospital of Southwest Jiaotong University, The Third People's Hospital of Chengdu, Chengdu, Sichuan, China. lhanx@126.com.

Förderung

  • Liu Hanxiong Famous Doctor Studio of Chengdu

Zitieren

APA

Xiong, S., Luo, D., Luo, Y., Yang, G., He, G., Yang, Y., He, J., Xu, B., Cai, L., Huang, L., Chen, H., Thomas, G., Betts, T., Zhang, Z., & Liu, H. (2026). First-in-human experience and one-year outcomes using a novel conformal pulsed-field ablation balloon catheter for pulmonary vein isolation in paroxysmal atrial fibrillation. Journal of Interventional Cardiac Electrophysiology, 69(9), 3157-3167. https://doi.org/10.1007/s10840-026-02447-y

Vancouver

Xiong S, Luo D, Luo Y, Yang G, He G, Yang Y, et al. First-in-human experience and one-year outcomes using a novel conformal pulsed-field ablation balloon catheter for pulmonary vein isolation in paroxysmal atrial fibrillation. Journal of Interventional Cardiac Electrophysiology. 2026;69(9):3157-3167. doi:10.1007/s10840-026-02447-y

BibTeX
@article{Xiong2026,
  author = {Xiong, Shiqiang and Luo, Duan and Luo, Yan and Yang, Guoshu and He, Guijun and Yang, Yongxin and He, Jialing and Xu, Bao and Cai, Lin and Huang, Long and Chen, Hao and Thomas, George and Betts, Tim and Zhang, Zhen and Liu, Hanxiong},
  title = {First-in-human experience and one-year outcomes using a novel conformal pulsed-field ablation balloon catheter for pulmonary vein isolation in paroxysmal atrial fibrillation},
  journal = {Journal of Interventional Cardiac Electrophysiology},
  year = {2026},
  volume = {69},
  number = {9},
  pages = {3157--3167},
  doi = {10.1007/s10840-026-02447-y}
}
Kostenlos starten →